Apogee Therapeutics, Inc. (APGE)
85.62
+2.90
(+3.51%)
USD |
NASDAQ |
Jun 11, 12:09
Apogee Therapeutics Enterprise Value : 5.142B for June 10, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 10, 2026 | 5.142B |
| June 09, 2026 | 5.313B |
| June 08, 2026 | 5.164B |
| June 05, 2026 | 5.457B |
| June 04, 2026 | 5.755B |
| June 03, 2026 | 5.253B |
| June 02, 2026 | 4.842B |
| June 01, 2026 | 4.886B |
| May 29, 2026 | 5.099B |
| May 28, 2026 | 4.776B |
| May 27, 2026 | 4.810B |
| May 26, 2026 | 5.191B |
| May 22, 2026 | 5.067B |
| May 21, 2026 | 5.163B |
| May 20, 2026 | 5.084B |
| May 19, 2026 | 4.849B |
| May 18, 2026 | 4.885B |
| May 15, 2026 | 5.065B |
| May 14, 2026 | 5.274B |
| May 13, 2026 | 5.276B |
| May 12, 2026 | 5.200B |
| May 11, 2026 | 5.326B |
| May 08, 2026 | 5.208B |
| May 07, 2026 | 5.116B |
| May 06, 2026 | 5.322B |
| Date | Value |
|---|---|
| May 05, 2026 | 5.227B |
| May 04, 2026 | 5.247B |
| May 01, 2026 | 5.032B |
| April 30, 2026 | 5.193B |
| April 29, 2026 | 5.128B |
| April 28, 2026 | 5.380B |
| April 27, 2026 | 5.463B |
| April 24, 2026 | 5.398B |
| April 23, 2026 | 5.600B |
| April 22, 2026 | 5.780B |
| April 21, 2026 | 5.794B |
| April 20, 2026 | 5.798B |
| April 17, 2026 | 5.895B |
| April 16, 2026 | 5.770B |
| April 15, 2026 | 5.678B |
| April 14, 2026 | 5.612B |
| April 13, 2026 | 5.482B |
| April 10, 2026 | 5.447B |
| April 09, 2026 | 5.466B |
| April 08, 2026 | 5.209B |
| April 07, 2026 | 5.221B |
| April 06, 2026 | 5.276B |
| April 02, 2026 | 5.301B |
| April 01, 2026 | 5.294B |
| March 31, 2026 | 5.251B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Evommune, Inc. | 535.67M |
| Cogent Biosciences, Inc. | 4.797B |
| Kymera Therapeutics, Inc. | 5.859B |
| Erasca, Inc. | 3.958B |
| GRAIL, Inc. | 1.638B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -74.11M |
| Total Expenses (Quarterly) | 74.11M |
| EPS Diluted (Quarterly) | -1.064 |
| Earnings Yield | -5.05% |
| Normalized Earnings Yield | -5.054 |